公开(公告)号：US11820778B2

公开(公告)日：2023-11-21

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11485742B2

公开(公告)日：2022-11-01

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US12122761B2

公开(公告)日：2024-10-22

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11548865B2

公开(公告)日：2023-01-10

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11905283B2

公开(公告)日：2024-02-20

申请号：US17130374

申请日：2020-12-22

Applicant: Novartis AG

Inventor： Zhuoliang Chen ,  Jorge Garcia Fortanet ,  Rajesh Karki ,  Matthew J. Lamarche ,  Dyuti Majumdar ,  Lawrence Blas Perez ,  Martin Sendzik ,  Troy Douglas Smith ,  Fan Yang ,  Bing Yu

IPC: C07D471/04 ,  C07D401/14 ,  C07D403/14 ,  C07D455/02 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D403/14 ,  C07D455/02 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I:






in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US10934285B2

公开(公告)日：2021-03-02

申请号：US16309076

申请日：2017-06-12

Applicant: Novartis AG

Inventor： Zhuoliang Chen ,  Jorge Garcia Fortanet ,  Rajesh Karki ,  Matthew J. Lamarche ,  Dyuti Majumdar ,  Lawrence Blas Perez ,  Martin Sendzik ,  Troy Douglas Smith ,  Fan Yang ,  Bing Yu

IPC: C07D487/14 ,  C07D471/04 ,  C07D401/14 ,  C07D403/14 ,  C07D455/02 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.